Reviva Pharmaceuticals Holdings (RVPH) Cash from Financing Activities (2018 - 2026)

Reviva Pharmaceuticals Holdings has reported Cash from Financing Activities for 8 years, with the latest figure at $11.6 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 158787.84% year-over-year to $11.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.1 million (up 59.05% YoY) and the FY2025 annual result came in at $25.6 million, up 8.05% from the prior year.
• Cash from Financing Activities grew to $11.6 million in Q1 2026 per RVPH's latest filing, from $7.1 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $27.3 million in Q4 2023 and troughed at $70.0 in Q1 2022.
• A 5-year average of $6.8 million and a median of $5.2 million in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities soared 981461.43% in 2023, then plunged 97.81% in 2025.
• Over 5 years, Cash from Financing Activities stood at $18563.0 in 2022, then jumped by 146813.77% to $27.3 million in 2023, then sank by 37.6% to $17.0 million in 2024, then plunged by 58.55% to $7.1 million in 2025, then soared by 63.78% to $11.6 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $11.6 million, $7.1 million, and $8.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.